![Quiver Logo](/static/img/logo-icon.png)
![DAWN logo](https://quiver-logos.s3.us-east-2.amazonaws.com/dawn.png)
Day One Biopharmaceuticals, Inc. Common Stock
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view DAWN Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of DAWN by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by DAWN's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to DAWN
Recent picks made for DAWN stock on CNBC
ETFs with the largest estimated holdings in DAWN
Flights by private jets registered to DAWN
![Quiver Logo](/static/img/logo-icon.png)